TRCT
CTXR icon

Tower Research Capital (TRC)’s Citius Pharmaceuticals CTXR Stock Holding History

Tower Research Capital (TRC)’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.51K Sell
2,785
-23
-0.8% -$19 ﹤0.01% 4466
2025
Q4 		$2.18K Buy
+2,808
New +$3.51K ﹤0.01% 4572
2025
Q2 		– Sell
-4,410
Closed -$6.57K – 5301
2025
Q1 		$6.57K Sell
4,410
-3,802
-46% -$9.1K ﹤0.01% 4032
2024
Q4 		$32.8K Buy
8,212
+8,050
+4,969% +$54.2K ﹤0.01% 2835
2024
Q3 		$2.02K Sell
162
-1,579
-91% -$26.6K ﹤0.01% 5060
2024
Q2 		$25.4K Buy
1,741
+1,413
+431% +$25.3K ﹤0.01% 3606
2024
Q1 		$7.35K Sell
328
-199
-38% -$3.63K ﹤0.01% 4220
2023
Q4 		$9.97K Sell
527
-129
-20% -$2.45K ﹤0.01% 4316
2023
Q3 		$11.2K Buy
656
+297
+83% +$7.06K ﹤0.01% 4021
2023
Q2 		$10.8K Buy
+359
New +$11.8K ﹤0.01% 4066
2023
Q1 		– Sell
-22
Closed – – 5875
2022
Q4 		$0 Sell
22
-137
-86% -$3.74K ﹤0.01% 5950
2022
Q3 		$5K Buy
+159
New +$4.37K ﹤0.01% 5131
2022
Q2 		– Sell
-267
Closed -$12K – 6131
2022
Q1 		$12K Sell
267
-188
-41% -$7.42K ﹤0.01% 4049
2021
Q4 		$17K Buy
455
+80
+21% +$3.63K ﹤0.01% 3840
2021
Q3 		$19K Sell
375
-29
-7% -$1.46K ﹤0.01% 3750
2021
Q2 		$35K Sell
404
-1,610
-80% -$96.8K ﹤0.01% 3320
2021
Q1 		$90K Buy
+2,014
New +$80.2K ﹤0.01% 2668
2020
Q4 		– Sell
-337
Closed -$9K – 5155
2020
Q3 		$9K Sell
337
-772
-70% -$21.8K ﹤0.01% 4132
2020
Q2 		$31K Buy
+1,109
New +$24.3K ﹤0.01% 3412

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Tower Research Capital (TRC)'s CTXR Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Citius Pharmaceuticals (CTXR) stake by 0.82% in Q1 2026, selling an estimated $19 and leaving 2,785 shares worth $2.51K. The position accounts for ﹤0.01% of the portfolio, ranked #4466.

Tower Research Capital (TRC) first reported a position in CTXR in Q2 2020 and has held it in 19 quarters since. The position peaked at $90K in Q1 2021. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

  • Tower Research Capital (TRC) held 2,785 shares of Citius Pharmaceuticals worth $2.51K as of Q1 2026.
  • Tower Research Capital (TRC) sold 23 Citius Pharmaceuticals shares in Q1 2026, an estimated $19.
  • Citius Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4466 holding.
  • Tower Research Capital (TRC) first reported a position in Citius Pharmaceuticals in Q2 2020 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s Citius Pharmaceuticals position peaked at $90K in Q1 2021.
  • 38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.